Drug Discovery 2022: driving the next life science revolution

4 October

Wed 5 October

[Schedule with Sessions only]

DAY 1

Auditorium 1

Auditorium 2

Auditorium 3

Auditorium 4

DAY 2

8:00

Registration

Early Career Professional (ECP) Meet & Greet

8:00:

8:05:

8:10:

8:15:

8:20:

8:25:

8:30:

8:35:

8:40:

8:45:

8:50:

8:55:

9:00

Conference Welcome and Keynote Introduction

9:00:

9:05:

Keynote Presentation

Genomic Sciences in Immunology – Strategies for Finding Future Drug Targets through Genetics, Functional Genomics and Immunophenotyping
09:05 (45 mins)
Rabinder Prinjha, GlaxoSmithKline

9:05:

9:10:

9:15:

9:20:

9:25:

9:30:

9:35:

9:40:

9:45:

9:50:

ELRIG - Early Career Professional Impact Award - Supported by Elemental Machines

Early Career Professional Introduction
09:50 (5 mins)
Mark Soave, OMass Therapeutics

Pandemic response: accessible BSL3 platforms for drug discovery
09:55 (20 mins)
Shaun Pennington, LSTM

9:50:

9:55:

10:00

10:05

10:10

10:15

Poster Prize Awards

10:15

10:20

Refreshment Break

DDW - The lab of the future is now: Using AI or automation for the discovery process - Sponsored by Elemental Machines

Chairs: Nicola Richmond, BenevolentAI

Science Solutions Recruitment - Futureproof your career in Drug Discovery - Panel Discussion

Chairs: Paul Mears, Science Solutions Recruitment Andrew Ratcliffe, Domainex Ltd

10:20

10:25

10:30

10:35

10:40

10:45

10:50

10:55

11:00

Developments in Preclinical Models

Chairs: Lisa Mohamet, GlaxoSmtihKline Samantha Barichievy, AstraZeneca AB

Session Introduction
11:00 (5 mins)
Lisa Mohamet, GlaxoSmtihKline Samantha Barichievy, AstraZeneca AB

Biomarker Discovery Using Preclinical Models: Resources, Challenges and Opportunities
11:05 (30 mins)
Benjamin Haibe-Kains, Princess Margaret Cancer Centre

Developments in Cytometry Technology to Enhance Pre-Clinical Workflows: StarBright Dyes and the ZE5 Cell Analyzer
11:35 (30 mins)
Richard Cuthbert — Bio-Rad

Utilising complex in vitro gut models in drug discovery: they needn’t be hard to stomach
12:05 (30 mins)
Nathaniel Lam, GSK

Using human iPSC technology to model disease-relevant signatures of Alzheimer's disease and other tauopathies
12:35 (15 mins)
Laura Calo — Ncardia

Innovation through partnership - Sponsored by AstraZeneca Open Innovation

Chairs: Kathryn Chapman, Milner Therapeutics Institute, University of Cambridge David Powell, LifeArc

Session Introduction
11:00 (5 mins)
Kathryn Chapman, Milner Therapeutics Institute, University of Cambridge David Powell, LifeArc

KQ Labs accelerator for data driven health start-ups: why does it exist, what does it do and what difference does it make?
11:05 (30 mins)
Barbara Domayne-Hayman, Francis Crick Institute Jelena Aleksic, PharmEnable

Developing strategic partnerships to accelerate worldwide access to human cells
11:35 (30 mins)
Kam Dhaliwal — bit.bio David Fischer — bit.bio

The Joint AstraZeneca-Cancer Research Horizon Functional Genomics Centre (FGC): A partnership demonstrating how together we innovate faster and impact more
12:05 (30 mins)
Douglas Ross-Thriepland, AstraZeneca

Beyond Small Molecules…
12:35 (15 mins)
David Madge — WuXi AppTec

Advancements in Screening and Automation Sponsored by IDBS

Chairs: Mario Richter, AbbVie Deutschland GmbH & Co. KG Kirsten Tschapalda, Roche

Session Introduction
11:00 (5 mins)
Mario Richter, AbbVie Deutschland GmbH & Co. KG Kirsten Tschapalda, Roche

Efficient low-priced custom automation at Abbvie
11:05 (30 mins)
Mario Richter, AbbVie Deutschland GmbH & Co. KG

Automated analysis workflow to identify metal contamination in HTS outputs
11:35 (30 mins)
Rachel Moore — Genedata AG

iPSC automation platform
12:05 (30 mins)
Martine Geraerts, UCB Biopharma

Multiparametric drug discovery facilitated by automated liquid handling
12:35 (15 mins)
Mark Graham — Beckman Coulter UK Ltd.

Frontiers of chemistry applied to drug discovery

Chairs: A Ganesan, University Of East Anglia Mary Wheldon, Drug Discovery Unit, University of Dundee Martin Swarbrick, Ryvu Therapeutics Becky Garton, Royal Society of Chemistry

Session Introduction
11:00 (5 mins)
A Ganesan, University Of East Anglia Martin Swarbrick, Ryvu Therapeutics Mary Wheldon, Drug Discovery Unit, University of Dundee Becky Garton, Royal Society of Chemistry

Platforms for the generation and high-throughput screening of cyclic peptide libraries.
11:05 (30 mins)
Ali Tavassoli, Curve Therapeutics & University of Southampton

Green Chemistry at GSK - How and when to use guides, and using Green Chemistry to design a scalable route to a first-in-class BET BD2 inhibitor
11:35 (30 mins)
Catherine Alder, GSK

Ligand discovery in dark chemical space leading to biological insights
12:05 (30 mins)
John Irwin, University of California San Francisco

Oxford Nanopore Technologies - a look into the complete genome
12:35 (15 mins)
Daniel Fordham — Oxford Nanopore Technologies

11:00

11:05

11:10

11:15

11:20

11:25

11:30

11:35

11:40

11:45

11:50

11:55

12:00

12:05

12:10

12:15

12:20

12:25

12:30

12:35

12:40

12:45

12:50

Refreshment Break - Poster Session 13.15 - 13.45

DDW - The sustainable lab. Building a global culture of sustainability in science

Panel discussion - Entrepreneurial Start Ups 101: Catalysing Innovation in Biomedical Science - chaired by Del Trezise

Chairs: Tom Fleming, Arctoris Michael Salako, Start Codon Hanadi Jabado, Sana Capital Margaret Anne Craig, Axol Bioscience

12:50

12:55

1:00

1:00:

1:05:

1:10:

1:15:

1:20:

1:25:

1:30:

DDW - The automated lab and the human

Chairs: Adam Prosho, CBRE-GWS

1:30:

1:35:

1:40:

1:45:

1:50:

1:55:

2:00

Developments in Preclinical Models

Organoid Biobanks for Cancer Drug Discovery
14:00 (30 mins)
Mathew Garnett, Wellcome Sanger Institute

New/Novel/Ground-breaking technologies assisting the sustainable preclinical drug discovery
14:30 (5 mins)
Karthi Rajamani — Takara Bio

From HTS Campaign to Biophysical Characterization: The Art of Generating Promising Hit Series for PIM3 Kinase
14:35 (5 mins)
Celine Legros — Eurofins Discovery

Upgrading African disease-in-a-dish models for pharmacovigilance: Enter the humble cell
14:40 (30 mins)
Janine Scholefield, CSIR, South Africa

Innovation through partnership - Sponsored by AstraZeneca Open Innovation

The Drug Discovery Unit: Leading the development of new anti-infective treatments with a collaborative approach
14:00 (30 mins)
Beatriz Baragana, Drug Discovery Unit, University of Dundee

Pressure over liquid – Established technology but with new value
14:30 (5 mins)
Paul Kendall — FESTO

Building a Strong Digital Foundation to Accelerate Innovation and Drug Discovery
14:35 (5 mins)
Oliver Pentinmaki — Benchling

Dementia Drugs through Partnership at the ALBORADA Drug Discovery Institute
14:40 (30 mins)
John Skidmore, University of Cambridge

Advancements in Screening and Automation Sponsored by IDBS

Collaborative AMR Implementation in Biopharmaceutical Labs
14:00 (30 mins)
Thomas Albanetti, AstraZeneca

HTS Assay detection at its best! - New PHERAstar FSX features improve data quality and sample processing
14:30 (5 mins)
Catherine Wark — BMG LABTECH Ltd

Cost Effective Decapping
14:35 (5 mins)
Adam McGinnis — Azenta Life Sciences

An Educational Approach for Drug Discover Using AI Driven Closed Loop Experimentation
14:40 (30 mins)
Joshua Kangas, Carnegie Mellon University

Frontiers of chemistry applied to drug discovery

Discovery of the clinical candidate, ASTX029, a dual mechanism ERK inhibitor
14:00 (30 mins)
Nicola Wallis, Astex

Flow Induced Dispersion Analysis (FIDA) Protein QC: Linking absolute hydrodynamic radius determination to structural insight.
14:30 (5 mins)
Joanne Walter — Fida Biosystems ApS

TargetMol：Targets small molecules in drug discovery
14:35 (5 mins)
Phoebe Feng — Targetmol Chemicals Inc.

The Discovery and Clinical Efficacy of Sisunatovir
14:40 (30 mins)
Stuart Cockerill, Reviral/Pfizer

2:00:

2:05:

2:10:

2:15:

2:20:

2:25:

2:30:

2:35:

2:40:

2:45:

2:50:

2:55:

3:00

3:00:

3:05:

3:10:

Refreshment Break

3:10:

3:15:

DDW - The remote lab: Is this the future?

Chairs: Martin-Immanuel Bittner, Arctoris

3:15:

3:20:

3:25:

3:30:

3:35:

3:40:

3:45:

Developments in Preclinical Models

Generating improved preclinical models for profiling novel combinations
15:45 (30 mins)
Elizabeth Hardaker, Astrazeneca

Image-based drug screening in patient biopsies for personalized systems medicine and drug discovery
16:15 (30 mins)
Berend Snijder , ETH Zurich

Innovation through partnership - Sponsored by AstraZeneca Open Innovation

The benefits of working side-by-side: The Crick-GSK Biomedical LinkLabs collaboration.
15:45 (30 mins)
Katrin Rittinger, Francis Crick Institute Andrew Powell, GlaxoSmithKline

Advancing UK Medicines Discovery through Innovative Partnerships
16:15 (30 mins)
Martin Main, Medicines Discovery Catapult

Advancements in Screening and Automation Sponsored by IDBS

Enhancing the lead discovery assay value chain by an orchestrated lab automation ecosystem
15:45 (30 mins)
Federica Morandi, F Hoffmann-La Roche Kirsten Tschapalda, Roche

High Throughput Affinity Screening for Rapid Hit Discovery and Prosecuting Challenging Targets
16:15 (30 mins)
Poppy Llowarch, AstraZeneca

Frontiers of chemistry applied to drug discovery

Discovery and Development of Pyrukynd®: The First-in-Class Pyruvate Kinase Activator For The Treatment of Hemolytic Anemia
15:45 (30 mins)
Lenny Dang, Agios Pharmaceuticals Inc

Simplifying Synthesis with Electricity
16:15 (45 mins)
Phil Baran, Scripps Research Institute

3:45:

3:50:

3:55:

4:00

4:00:

4:05:

4:10:

4:15:

4:20:

4:25:

4:30:

4:35:

4:40:

4:45:

4:50:

4:55:

5:00

5:00:

5:05:

5:10:

5:15:

5:20:

5:25:

5:30:

5:35:

5:40:

5:45:

5:50:

5:55:

6:00

6:00:

6:05:

6:10:

6:15:

6:20:

6:25:

6:30:

6:35:

6:40:

6:45:

6:50:

6:55:

7:00

7:00: